Phenazines (including Hydrogenated) Patents (Class 544/347)
  • Patent number: 9351971
    Abstract: The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapes, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: May 31, 2016
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
  • Patent number: 9216974
    Abstract: The present invention encompasses phenoxazine derivatives and methods of use thereof.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: December 22, 2015
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory Zipfel, Byung Han, Robert Mach, Wenhua Chu
  • Patent number: 9040700
    Abstract: A process of making a polymeric phenazonium compound having the general formula: wherein R1, R2, R4, R5, R6, R8, and R9 are the same or different, and represent hydrogen, a low alkyl or a substituted aryl, R3 starts with NH2 and is diazotized followed by a polymerization, R5 and R8 may alternatively represent monomeric or polymeric phenazonium radicals, R7 is a carbon in the aromatic ring, Rx and Ry represent any combination of CH3, C2H5, and hydrogen, except that Rx and Ry cannot both be hydrogen, A is an acid radical, and n is an integer from 2 to 100, preferably from 2 to 20 is described. The polymeric phenazonium compound is usable as an additive in a metal plating bath comprising copper.
    Type: Grant
    Filed: February 17, 2014
    Date of Patent: May 26, 2015
    Inventors: Andrew M. Krol, Ernest Long, Lev Taytsas
  • Patent number: 9000164
    Abstract: An organic electroluminescence (EL) material and an organic EL device including the same, the organic electroluminescence (EL) material being represented by following Chemical Formula 1:
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: April 7, 2015
    Assignee: Samsung Display Co., Ltd.
    Inventor: Hiroaki Itoi
  • Patent number: 8999967
    Abstract: Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: April 7, 2015
    Assignee: Presidio Pharmaceuticals, Inc.
    Inventors: Leping Li, Min Zhong
  • Patent number: 8987271
    Abstract: The invention relates to a chemotherapeutic cancer treatment in which compounds (BH3Is) are administered to a mammal to treat B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. The invention also provides a method for treating types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more disclosed compounds in combination with other therapies, for example, 26S proteosome inhibitors, such as, for example, Bortezomib. The invention also relates to autoimmune treatment with pharmaceutical compositions comprising one or more disclosed compounds. The invention also relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 24, 2015
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
  • Publication number: 20140275045
    Abstract: Disclosed herein are phenazine-3-one and phenothiazine-3-one derivative compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 18, 2014
    Applicant: EDISON PHARMACEUTICALS, INC.
    Inventors: Andrew W. HINMAN, Dana Davis, William D. Shrader
  • Patent number: 8802975
    Abstract: Provided are compounds with a donor moiety, a first acceptor moiety and a second acceptor moiety, as shown by Formula (I): With the unique molecular design, compounds of Formula (I) can provide a desirable power conversion efficiency. Moreover, this invention also provides organic thin-film solar cells comprising the above-mentioned compounds.
    Type: Grant
    Filed: January 3, 2012
    Date of Patent: August 12, 2014
    Inventors: Ken-Tsung Wong, Hao-Wu Lin, Li-Yen Lin, Francis Lin, Yi-Hong Chen, Shi-Wen Chiu
  • Patent number: 8735580
    Abstract: A process of making a polymeric phenazonium compound having the general formula: wherein R1, R2, R4, R5, R6, R8 and R9 are the same or different, and represent hydrogen, a low alkyl or a substituted aryl, R3 starts as NH2 and is diazotized followed by polymerization, R5 and R8 may alternatively represent monomeric or polymeric phenazonium radicals, R7 is a carbon in the aromatic ring, and wherein RX—N—RY represents a substituted amine, and RX and RY represent any combination of CH3, C2H5, and hydrogen, except that RX and RY cannot both be hydrogen, A is an acid radical, and n is an integer from 2 to 100. The polymeric phenazonium compound is usable in as an additive in a metal plating bath.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: May 27, 2014
    Inventors: Andrew M. Krol, Ernest Long, Lev Taytsas
  • Publication number: 20140114063
    Abstract: An organic electroluminescence (EL) material and an organic EL device including the same, the organic electroluminescence (EL) material being represented by following Chemical Formula 1:
    Type: Application
    Filed: October 18, 2013
    Publication date: April 24, 2014
    Applicant: Samsung Display Co., Ltd.
    Inventor: Hiroaki ITOI
  • Patent number: 8691987
    Abstract: A process of making a polymeric phenazonium compound having the general formula: wherein R1, R2, R4, R5, R6, R8 and R9 are the same or different, and represent hydrogen, a low alkyl or a substituted aryl, R3 starts with NH2 and is diazotized followed by polymerization, R5 and R8 may alternatively represent monomeric or polymeric phenazonium radicals, R7 with its substituent group is a substituted amine, with RX and RY representing any combination of CH3, C2H5, and hydrogen, except that RX and RY cannot both be hydrogen, A is an acid radical, and n is an integer from 2 to 100, preferably from 2 to 20 is described. The polymeric phenazonium compound is usable in as an additive in a metal plating bath.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: April 8, 2014
    Inventors: Andrew M. Krol, Ernest Long, Lev Taytsas
  • Publication number: 20140093453
    Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), LABORATOIRES CYCLOPHARMA, UNIVERSITE D'AUVERGNE CLERMONT 1, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Jean-Michel CHEZAL, Frederic DOLLE, Jean-Claude MADELMONT, Aurelie MAISONIAL, Elisabeth MIOT-NOIRAULT, Nicole MOINS, Janine PAPON, Bertrand KUHNAST, Bertrand TAVITIAN, Raphael BOISGARD
  • Publication number: 20140070146
    Abstract: The present application relates to a compound of a formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
    Type: Application
    Filed: April 12, 2012
    Publication date: March 13, 2014
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Arne Buesing, Christof Pflumm, Teresa Mujica-Fernaud, Philipp Stoessel, Thomas Eberle
  • Patent number: 8669257
    Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of W, Q, R1, R2, R3, R4, R5, m, and n is as defined herein, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: March 11, 2014
    Assignee: The Johns Hopkins University
    Inventors: Jun O. Liu, Yunzhao Ren, Fan Pan, Curtis R. Chong, Reinhold Penner, Jonathan R. Behr
  • Publication number: 20140058099
    Abstract: The compounds represented fey the following general formula is is thermally stable and has excellent characteristics as a charge transport material [Ar1 represents a single bond, a benzene ring, etc.; X1 represents a linking group that links via an oxygen atom, a sulfur atom, a carbon atom, a nitrogen atom, a phosphorus atom or a silicon atom; either one of L1 and L2, and L3 and L4 bond to each other to represent a linking group that links via an oxygen atom, a sulfur atom, a carbon atom, a nitrogen atom, a phosphorus atom or a silicon atom; the other of L1 and L2, and L3 and L4 represent a hydrogen atom or a substituent; Y1 represents a linking group that links via a nitrogen atom, a boron atom or a phosphorus atom; R1, R2, R5 to R7 and R10 to R12 represent a hydrogen atom or a substituent; and n1 indicates an integer of 2 or more.].
    Type: Application
    Filed: March 2, 2012
    Publication date: February 27, 2014
    Applicant: KYUSHU UNIVERSITY NATIONAL UNIVERSITY CORPORATION
    Inventors: Atsushi Wakamiya, Hidetaka Nishimura, Yasujiro Murata, Tatsuya Fukushima, Hironori Kaji
  • Publication number: 20140042412
    Abstract: A compound for an organic optoelectronic device is represented by the following Chemical Formula 1:
    Type: Application
    Filed: October 11, 2013
    Publication date: February 13, 2014
    Inventors: Dong-Wan RYU, Sung-Hyun JUNG, Dal-Ho HUH, Jin-Seok HONG, Gi-Wook KANG, Mi-Young CHAE
  • Publication number: 20140004051
    Abstract: The invention provides co-crystals and salts of contrast agents as well as methods to use and prepare the co-crystals and salts.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 2, 2014
    Inventor: Leonard R. MacGillivray
  • Publication number: 20130315825
    Abstract: Derivatives of phenothiazine, phenoxazine, and phenazine compounds and their use as ?-synuclein ligands are described. Also described are methods of using these compounds and their radiolabeled analogs for the detection, monitoring, and treatment of synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: May 3, 2013
    Publication date: November 28, 2013
    Applicant: Washington University
    Inventors: Zhude Tu, Robert Mach, Lihai Yu, Paul Kotzbauer
  • Publication number: 20130296304
    Abstract: Provided herein are compounds, pharmaceutical compositions and combination therapies for treatment of hepatitis C.
    Type: Application
    Filed: September 28, 2011
    Publication date: November 7, 2013
    Applicant: PRESIDIO PHARMACEUTICALS, INC.
    Inventors: Leping Li, Min Zhong
  • Publication number: 20130019949
    Abstract: Provided are compounds with a donor moiety, a first acceptor moiety and a second acceptor moiety, as shown by Formula (I): With the unique molecular design, compounds of Formula (I) can provide a desirable power conversion efficiency. Moreover, this invention also provides organic thin-film solar cells comprising the above-mentioned compounds.
    Type: Application
    Filed: January 3, 2012
    Publication date: January 24, 2013
    Inventors: KEN-TSUNG WONG, HAO-WU LIN, LI-YEN LIN, FRANCIS LIN, YI-HONG CHEN, SHI-WEN CHIU
  • Patent number: 8283053
    Abstract: To provide a high-performance organic light emitting device and a novel compound possessed by the device. Provided are a novel fluoranthene derivative and an organic light emitting compound having the derivative.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: October 9, 2012
    Assignee: Canon Kabushiki Kaisha
    Inventors: Masashi Hashimoto, Akihito Saitoh, Naoki Yamada, Satoshi Igawa, Jun Kamatani, Takao Takiguchi, Shinjiro Okada
  • Publication number: 20120251491
    Abstract: The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: May 12, 2010
    Publication date: October 4, 2012
    Inventors: Stuart B. Rosenblum, Kevin X. Chen, Joseph A. Kozlowski, F. George Njoroge, Craig A. Coburn
  • Patent number: 8273881
    Abstract: The invention discloses compounds, compositions and methods useful for preventing and/or treating autoimmune diseases and inflammatory diseases. The methods and compositions utilize water-soluble phenazine compounds, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent autoimmune diseases and inflammatory diseases such as those caused by arthritis and rheumatoid arthritis.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: September 25, 2012
    Assignee: JJ Pharma, Inc.
    Inventor: Josefino B. Tunac
  • Publication number: 20120227802
    Abstract: The present invention provides a organic compound of the general structural formula 1 and photovoltaic device and photovoltaic layer comprising thereof Said organic compound forms rod-like supramolecules and absorbs electromagnetic radiation in at least one predetermined spectral subrange within a wavelength range from 400 to 3000 nm with excitation of electron-hole pairs. The polycyclic core Cor1, the bridging group B, and the polycyclic core Cor2 form a molecular system selected from the list comprising donor-bridge-acceptor-bridge-donor and acceptor-bridge-donor-bridge-acceptor in which a dissociation of excited electron-hole pairs is carried out. A solution of the organic compound or its salt forms a solid photovoltaic layer on a substrate.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 13, 2012
    Applicant: Cryscade Solar Limited
    Inventors: Pavel KHOKHLOV, Pavel Ivan Lazarev, Alexey Nokel
  • Publication number: 20120225851
    Abstract: The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia?, Ib?, Ic?, or II? (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia?, Ib?, Ic?, or II?.
    Type: Application
    Filed: December 22, 2011
    Publication date: September 6, 2012
    Applicant: EUTROPICS PHARMACEUTICALS, INC.
    Inventors: Michael H. Cardone, Xiang Y. Yu, Andrew F. Kolodziej
  • Publication number: 20120101427
    Abstract: The present invention provides novel drug formulations for oral administration for diverse medical applications including anticancer, antimetastatic, antibacterial, antifungal, antiprotozoic, antiviral, antiprionic and PDT treatments for diagnostic and therapeutic purposes. In a preferred embodiment the oral drug formulation comprises a photosensitizer and suitable excipients and may be administered in multiple doses over an extended period of time with exposure to activating radiation occurring generally between individual doses or in a light-independent manner. In another preferred embodiment PDT methods for treating hyperplasia and neoplasia, for localizing hyperplasic and neoplasic tissues and pathogen bacteria by fluorescence, for treating infections caused by pathogen bacteria in complex body fluids and for fat reduction, skin disorders and vascular diseases are provided.
    Type: Application
    Filed: April 28, 2009
    Publication date: April 26, 2012
    Inventors: Gerard Farmer, Gerhard Wieland, Dietrich Scheglmann, Arno Wiehe, Susanna Gräfe, Nikolay E. Nufantiev, Volker Albrecht, Wolfgang Neuberger
  • Patent number: 8152903
    Abstract: Hindered cyclic polyamines and their salts are absorbents useful in acid gas treatment processes.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: April 10, 2012
    Assignee: ExxonMobile Research & Engineering Company
    Inventors: Michael Siskin, Alan R Katritzky, Edmund J. Mozeleski, Frank Cheng-Yu Wang
  • Publication number: 20110037027
    Abstract: The present invention relates to fluorine derivatives and organic electronic devices in which said compounds are used as a matrix material in the emitting layer and/or as a hole transport material, and/or as an electron blocking or exciton blocking material, and/or as an electron transport material.
    Type: Application
    Filed: March 11, 2009
    Publication date: February 17, 2011
    Inventors: Philipp Stoessel, Holger Heil, Dominik Joosten, Christof Pfumm, Anja Gerhard
  • Patent number: 7875712
    Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; ?between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: January 25, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Mortimore, Andrew Miller, John Studley, Jean-Damien Charrier
  • Patent number: 7872130
    Abstract: For the reproducible manufacturing of particularly uniform and brilliant i.e., highly bright copper coatings that are leveled and ductile as well, a copper plating bath is utilized that contains as an additive a mixture of oligomeric phenazinium compounds. The mixture contains at least one phenazinium compound selected from the group comprising compounds containing two monomeric units and compounds containing three monomeric units having the general chemical formulae <I> and <II> set forth in the patent claims and in the specification as well as further oligomeric phenazinium compounds.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: January 18, 2011
    Assignee: Atotech Deutschland GmbH
    Inventors: Heiko Brunner, Wolfgang Dahms, Thomas Moritz, Akif Özkök, Udo Grieser, Olanda Grieser, legal representative, Christopher Grieser, legal representative
  • Publication number: 20100331540
    Abstract: A method for producing a compound having a deuterated aromatic ring or heterocyclic ring according to the invention includes heating a compound having an aromatic ring or heterocyclic ring in the presence of heavy water, a transition metal and a metal which generates deuterium. As the metal which generates deuterium, at least one metal selected from the group consisting of aluminum, magnesium, zinc, iron, lead and tin is preferred. As the transition metal, at least one metal selected from the group consisting of platinum, palladium, ruthenium and rhodium is preferred. The heating is preferably carried out by microwave irradiation.
    Type: Application
    Filed: January 30, 2009
    Publication date: December 30, 2010
    Inventors: Haruki Shimodaira, Toshifumi Abe, Akira Miyazawa, Yuji Kawanishi, Taichi Abe
  • Publication number: 20100273803
    Abstract: Oral formulations and method of formulating photosensitive agents for oral administration during photodynamic therapy (PDT) and Antimicrobial photodynamic therapy (APDT) treatment are presented. The oral formulated photosensitizers show increased solubility and permeability, thus improving the bioavailability of photosensitizers at the treatment site. An orally administered photosensitizer is suitably formulated for mucosal adhesion and absorption via gastrointestinal mucosal membranes. Oral formulation provided herein use lipids and known proteins as carriers for photosensitizers by oral route. Carriers for encapsulating preselected photosensitizers include conventional liposomes, pegylated liposomes, nanoemulsions, nanocrystrals, nanoparticles, fatty emulsions, lipidic formulations, hydrosols, SMEDDS, Alpha-Feto protein (AFP), and Bovine-Serum-Albumin (BSA), fatty emulsions, hot-melt-extrudates and nanoparticles.
    Type: Application
    Filed: April 27, 2010
    Publication date: October 28, 2010
    Inventors: Susanna Gräfe, Nikolay Nifantiev, Albrecht Volker, Wolfgang Neuberger, Gerhard Wieland, Dietrich Scheglmann, Alfred Fahr, Arno Wiehe
  • Publication number: 20100190799
    Abstract: The invention discloses compounds, compositions and methods useful for preventing and/or treating autoimmune diseases and inflammatory diseases. The methods and compositions utilize water-soluble phenazine compounds, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent autoimmune diseases and inflammatory diseases such as those caused by arthritis and rheumatoid arthritis.
    Type: Application
    Filed: January 16, 2008
    Publication date: July 29, 2010
    Applicant: JJ PHARMA, INC.
    Inventor: Josefino B. Tunac
  • Publication number: 20100098630
    Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides.
    Type: Application
    Filed: December 28, 2007
    Publication date: April 22, 2010
    Applicant: AMBRX, INC.
    Inventor: Zhenwei Miao
  • Patent number: 7674793
    Abstract: The present invention is directed to novel tricyclic dihydropyrazine derivatives of Formula (I), pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: March 9, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Xuqing Zhang, Zhihua Sui
  • Publication number: 20100051106
    Abstract: Provided are novel organic electroluminescent compounds characterized in that they are represented by Chemical Formula (1): wherein, ring A and ring B independently represent a saturated 5- or 6-membered heterocyclic amino group, or a substituent selected from the following structures: wherein the saturated 5- or 6-membered heterocyclic amino group may further comprise one or more heteroatom(s) selected from NR36, O and S; and a and b independently represent an integer from 0 to 4, provided that (a+b) is an integer from 1 to 4.
    Type: Application
    Filed: June 23, 2009
    Publication date: March 4, 2010
    Applicant: Gracel Display Inc.
    Inventors: Chi Sik Kim, Young Jun Cho, Hyuck Joo Kwon, Bong Ok Kim, Sung Min Kim, Seung Soo Yoon
  • Publication number: 20090297414
    Abstract: Hindered cyclic polyamines and their salts are absorbents useful in acid gas treatment processes.
    Type: Application
    Filed: July 21, 2006
    Publication date: December 3, 2009
    Inventors: Michael Siskin, Alan R. Katritzky, Edmund John Mozeleski, Wang Frank Chen-Yu
  • Publication number: 20090259030
    Abstract: The present invention provides a new class of solids supports for synthesis of modified oligomers of nucleic acids, and nucleic acid probes that have a format expediently synthesized on the new supports. Exemplary solid supports include at least one quencher bound through a linker to the solid support. Various exemplary embodiments include a moiety that stabilizes a duplex, triplex or higher order aggregation (e.g., hybridization) of nucleic acids of which the oligomer of the invention is a component. Other components of the solid support include moieties that stabilize aggregations of nucleic acids, e.g., intercalators, minor groove binding moieties, bases modified with a stabilizing moiety (e.g., alkynyl moieties, and fluoroalkyl moieties), and conformational stabilizing moieties, such as those described in commonly owned U.S. Patent Application Publication No. 2007/0059752.
    Type: Application
    Filed: April 1, 2009
    Publication date: October 15, 2009
    Applicant: BIOSEARCH TECHNOLOGIES
    Inventors: Ronald M. Cook, Matt Lyttle
  • Publication number: 20090215736
    Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.
    Type: Application
    Filed: September 23, 2008
    Publication date: August 27, 2009
    Applicant: Vertex Pharmaceuticals, Incorporated
    Inventors: Michael Mortimore, Andrew Miller, John Studley, Jean-Damien Charrier
  • Publication number: 20090102371
    Abstract: To provide a high-performance organic light emitting device and a novel compound possessed by the device. Provided are a novel fluoranthene derivative and an organic light emitting compound having the derivative.
    Type: Application
    Filed: April 24, 2007
    Publication date: April 23, 2009
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Masashi Hashimoto, Akihito Saitoh, Naoki Yamada, Satoshi Igawa, Jun Kamatani, Takao Takiguchi, Shinjiro Okada
  • Publication number: 20090067030
    Abstract: Green electrochromic (EC) materials based on thiophene, and a green EC material based on pyrazine are disclosed. A first thiophene derivative (2,3-Di-thiophen-2-yl-thieno[3,4-b]pyrazine), which was previously investigated as a nonlinear optical material, is here disclosed for its use as an EC material and for its incorporation into an EC device. Synthesis of two new thiophene derivatives (2,5-di(thien-2-yl)-3,4-di(2,2,2-trifluoro-ethoxy)-thiophene and 2,5-(2,3-dihydro-thieno[3,4-b][1,4]dioxin-5-yl)-3,4-di(2,2,2-trifluoro-ethoxy)-thiophene), and a new pyrazine derivative (2,3-dibenzyl-5,7-di(thien-2-yl)thieno[3,4-b]pyrazine) are also disclosed, since these materials are all able to selectively change state to appear a green color and can be polymerized to achieve a green EC polymer.
    Type: Application
    Filed: October 22, 2007
    Publication date: March 12, 2009
    Applicant: University of Washington
    Inventors: Lu Liu, Chunye Xu, Minoru Taya
  • Patent number: 7465721
    Abstract: A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: December 16, 2008
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Serge Auvin, Pierre-Etienne Chabrier de Lassauniere
  • Publication number: 20080269231
    Abstract: The invention discloses compounds, compositions and methods useful for preventing and/or treating autoimmune diseases and inflammatory diseases. The methods and compositions utilize water-soluble phenazine compounds, or salts, or solvates thereof. These molecules can be delivered alone or in combination with agents which treat or prevent autoimmune diseases and inflammatory diseases such as those caused by arthritis and rheumatoid arthritis.
    Type: Application
    Filed: January 16, 2008
    Publication date: October 30, 2008
    Applicant: JJ Pharma, Inc.
    Inventor: Josefino B. Tunac
  • Patent number: 7442790
    Abstract: This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3is a group capable of fitting into the S2 subsite of a caspase enzyme; R4 is a hydrogen or C1-6 alkyl or R3 and R4 taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R5 are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1? secretion.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: October 28, 2008
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Michael Mortimore, Andrew Miller, John Studley, Jean-Damien Charrier
  • Publication number: 20080185555
    Abstract: Acene-based compounds that can be used to prepare n-type semiconductor materials are provided with processes for preparing the same. Composites and electronic devices including n-type semiconductor materials prepared from these compounds also are provided.
    Type: Application
    Filed: November 19, 2007
    Publication date: August 7, 2008
    Inventors: Antonio Facchetti, Tobin J. Marks, Zhiming M. Wang
  • Publication number: 20080167465
    Abstract: A compound for electrochromic devices. One such compound of the invention is dihydro-disubstituted phenazine (VI): wherein R9 is and n=1-10.
    Type: Application
    Filed: February 28, 2008
    Publication date: July 10, 2008
    Inventors: Donald Fitzmaurice, David Cummins, David Corr, S. Nagaraja Rao, Gerrit Boschloo
  • Patent number: 7384933
    Abstract: A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.
    Type: Grant
    Filed: April 27, 2005
    Date of Patent: June 10, 2008
    Assignee: Societe de Conseils de Recherches Et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Serge Auvin, Pierre-Etienne Chabrier De Lassauniere
  • Patent number: 7365194
    Abstract: A dimer of phenazine-1-carboyxlic acid natural products from fluorescent pseudomonad bacterium and a method of preparing a dimer of phenazine-1-carboxylic acid natural product are disclosed herein. The method comprises growing the bacterium in a water based liquid medium under favorable pH and temperature with continuous agitation, extracting the dimer of phenazine-1-carboyxlic acid natural product from the medium by centrifugation using organic solvents, filtering the resultant emulsion to separate the aqueous layer in a separation funnel, isolating the crude dimer of phenazine-1-carboyxlic acid natural product from the organic layer by evaporating the organic solvent, and purifying the dimer of phenazine-1-carboxylic acid natural product by chromatography.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: April 29, 2008
    Assignee: Pondicherry University and Department of Biotechnology
    Inventors: Natarajan Sakthivel, Radhakrishnan Sunish Kumar
  • Patent number: 7358358
    Abstract: A compound for use in electrochromic devices. The compound includes (1) ?-(10-phenothiazyl)propoxy phosphonic acid; (2) ?-(10-phenothiazyl)propyl-phosphonic acid; and (3) ?-(10-phenothiazyl)propionate phosphonic acid.
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: April 15, 2008
    Assignee: NTERA limited
    Inventors: Donald Fitzmaurice, David Cummins, David Corr, S. Nagaraja Rao, Gerrit Boschloo
  • Publication number: 20070191606
    Abstract: The present invention provides novel 2,2-bis(4-hydroxyphenyl)-alkyl onium salts as illustrated by 2,2-bis(4-hydroxyphenyl)-tridecyl(1,2-dimethylimidazolium)bromide and a process for preparation thereof by hydroxyalkylating acetoacetate to the corresponding hyroxyalkylacetoacetate, dealkoxycarbonylating the hydroxyalkyl acetoacetate to ?-hydroxyalkan-2-one and contacting the ?-hydroxyalkan-2-one with phenol in the presence of an acidic catalyst to give 2,2-bis(4-hydroxyphenyl)alkanol, brominating the 2,2-bis(4-hydroxyphenyl)alkanol to 2,2-bis(4-hydroxyphenyl)alkyl bromide, quaternizing 1,2-dimethylimidazole with the 2,2-bis(4-hydroxyphenyl)alkyl bromide to 2,2-bis(4-hydroxyphenyl)alkyl(1,2-dimethylimidazolium)bromide. The products can be used as reactive modifiers for layered phyllosilicates that can be used in the preparation of polymer-nanocomposites, wherein the said polymers are prepared from 2,2-bis(4-hydroxyphenyl)propane as one of the reacting monomers.
    Type: Application
    Filed: October 13, 2006
    Publication date: August 16, 2007
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Shroff Rama Mallikarjuna, Swaminathan Sivaram